Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆

Trackers› Clinical trials› Munich

Clinical trial register · Germany

Clinical Trials in Munich, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC

5051

Studies in scope

all four open statuses

2882

Recruiting now

open to new participants

988

Lead sponsors

across recruiting studies

Top sites

Hamburg 25 Berlin 24 Munich 22 Ulm 21 Freiburg im Breisgau 20

Narrow the registerReset

Search within results

Recruitment status

Lead sponsor

Clear sponsor filter

Site location

All 122 locations

Target enrolment

to

Trials with a site in Munich

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 3

990

Reutlingen, Munich, Dresden, Berlin, Hamburg

2026-05-22

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein

2025-11-05

Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110Plaque Psoriasis

AbbVie

Observational

700

Friedrichshafen, Kulmbach, Munich, Potsdam, Dortmund, Mainz, Mölln, Hamburg

2025-09-09

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Heidelberg, Munich, Würzburg, Hamburg

2025-07-23

Recruiting

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

NCT06916507Parkinson's Disease

AbbVie

Observational

125

Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich

2025-05-06

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Leucovorin·Fluorouracil

AbbVie

Phase 2

185

Freiburg im Breisgau, Munich, Frankfurt am Main, Leipzig, Hamburg

2024-12-13

Recruiting

A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

NCT06712628Moderate to Severe Rheumatoid Arthritis

AbbVie

Observational

678

Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich

2024-11-07

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda

2024-09-04

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Ulm, Munich, Ludwigshafen am Rhein, Leipzig, Kiel, Hamburg

2024-03-23

Active, closed

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426Parkinson's Disease (PD)

AbbVie

Observational

427

Wolfach, Munich, Potsdam, Osnabrück, Halle, Beelitz-Heilstätten, Bottrop

2024-01-24

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Erlangen, Munich, Blankenfelde-Mahlow, Bonn, Frankfurt am Main, Bad Bentheim, Münster, Mainz

2023-12-19

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugRisankizumab

AbbVie

Phase 3

110

Munich, Münster

2023-12-11

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Munich, Münster, Leipzig, Berlin

2023-11-06

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Munich, Bad Bentheim, Düsseldorf, Münster, Lübeck, Berlin

2023-10-11

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Munich, Dresden, Berlin

2022-12-05

Active, closed

Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

NCT05496348Ulcerative Colitis

AbbVie

Observational

400

Heidelberg, Winnenden, Augsburg, Dachau, Munich, Brandenburg an der Havel, Potsdam, Tostedt

2022-10-20

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

75

Mutlangen, Ulm, Landshut, Munich, Rostock, Cologne, Homburg, Dresden

2022-03-28

Active, closed

A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting

NCT05139836Atopic Dermatitis

AbbVie

Observational

634

Freiburg im Breisgau, Heidelberg, Langenau, Stuttgart, Freising, Memmingen, Munich, Nuremberg

2021-12-13

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Mannheim, Mutlangen, Munich, Hanover, Cologne, Düsseldorf, Leipzig, Berlin

2020-09-10

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Erlangen, Munich, Frankfurt am Main, Kassel

2018-08-28

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Cologne, Herne, Rendsburg, Chemnitz, Hamburg, Munich

2015-12-01

Active, closed

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

NCT01848561Ulcerative Colitis (UC)

AbbVie

Observational

8,250

Freiburg im Breisgau, Heidelberg, Mannheim, Sigmaringen, Ulm, Erlangen, Memmingen, Munich

2013-04-29

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/munich

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Munich that also match the filters currently applied.

How many clinical trials are recruiting in Munich?

10 of the 22 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Munich), 22 studies
Phase	Studies	Recruiting	Share
Phase 3	9	4	40.9%
Observational	7	3	31.8%
Phase 2	4	2	18.2%
Phase 1	1	0	4.5%
Phase 1/2	1	1	4.5%

Most active sponsors

Lead sponsors with the most studies (Munich)
Lead sponsor	Studies	Recruiting
AbbVie	22	10

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.